MYC and non-Hodgkin lymphoma: The modeled pharmacokinetic-pharmacodynamic relationship for MYC and MCL1 mRNA inhibition following C1D1 (Supplementary Fig. S2C), and the associated model fitted pharmacokinetics (Supplementary Fig. S2D) show that no differences were observed in pharmacokinetic and pharmacodynamic response between patients with DH-DLBCL and other MYC+ NHL.